Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic candidates for oncology. The company is dedicated to addressing significant unmet needs in cancer treatment by creating novel small molecules that enhance the efficacy of existing drugs. Nuvation Bio does not currently sell products but is engaged in research and development activities, with a focus on advancing its clinical-stage product candidates.
- NUV-868 - A BD2-selective oral small molecule BET inhibitor, evaluated in combination with other drugs for treating various cancers, including ovarian, pancreatic, and prostate cancers, as well as triple-negative breast cancer and other solid tumors.
- NUV-1511 - The first clinical candidate from the Drug-Drug Conjugate platform, undergoing evaluation in a Phase 1/2 study for advanced solid tumors.
- Taletrectinib - An oral, potent, CNS-active, selective, next-generation ROS1 inhibitor for advanced ROS1-positive non-small cell lung cancer, acquired through the acquisition of AnHeart Therapeutics Ltd. and evaluated in Phase 2 studies.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
David Hung, M.D. ExecutiveBoard | President, CEO, and Board Member | None | Founder of NUVB in April 2018; previously founded Medivation, Inc., leading development of Xtandi\u00ae and Talzenna\u00ae; Medivation was acquired by Pfizer for $14.3 billion. | |
Junyuan (Jerry) Wang, Ph.D. ExecutiveBoard | CEO of AnHeart Therapeutics and Director | None | Co-founder of AnHeart Therapeutics; led development of taletrectinib and safusidenib; extensive global regulatory experience; contributed to NDAs for Bosulif and Eliquis. | |
Colleen Sjogren Executive | Chief Commercial Officer | None | Joined NUVB in April 2024; previously held senior sales roles at Madrigal Pharmaceuticals, Mirati Therapeutics, and Kite Pharma. | |
Kerry Wentworth Executive | Chief Regulatory Officer | None | Joined NUVB in May 2022; previously Chief Regulatory Officer at Flexion Therapeutics; extensive regulatory leadership experience at Agenus and Genzyme. | |
Moses Makunje, CPA Executive | VP, Finance, Principal Financial and Accounting Officer | None | Joined NUVB in July 2020; promoted to VP, Finance in January 2022; appointed Principal Financial and Accounting Officer in November 2023; 16+ years of finance experience. | |
Philippe Sauvage Executive | Chief Financial Officer | None | Appointed CFO in October 2024; previously held senior finance roles at Sanofi, including CFO for Sanofi North America and Sanofi-Genzyme. | |
Stacy Markel Executive | Chief People Officer | None | Joined NUVB in October 2019 as SVP, Human Resources; promoted to Chief People Officer in January 2022; extensive HR leadership experience at Rigel Pharmaceuticals and Portola Pharmaceuticals. | |
Kathryn E. Falberg Board | Board Member, Chair of Audit Committee | Arcus Biosciences, The Trade Desk, Inc. | Former CFO of Jazz Pharmaceuticals and Amgen; extensive finance and strategy experience; serves on boards of Arcus Biosciences and The Trade Desk. | |
Kim Blickenstaff Board | Board Member | Executive Chairman and Chairman of Tandem Diabetes Care, Inc. | Extensive leadership experience in healthcare and medical devices; previously CEO of Biosite Incorporated; serves as Executive Chairman and Chairman of Tandem Diabetes Care. | |
W. Anthony Vernon Board | Board Member, Chair of Compensation Committee | NovoCure Ltd., Intersect ENT, Inc., McCormick & Co. | Former CEO of Kraft Foods Group; held senior roles at Johnson & Johnson; serves on boards of NovoCure, Intersect ENT, and McCormick & Co.. | |
Xiangmin (Min) Cui, Ph.D. Board | Board Member | Managing Director at Decheng Capital LLC; Board Member at Alpine Immune Sciences and multiple private companies | Founder of Decheng Capital; extensive leadership in biotech and pharma; serves on boards of Alpine Immune Sciences and several private companies. |
Research analysts who have asked questions during Nuvation Bio earnings calls.
Anish Nikhanj
RBC Capital Markets
2 questions for NUVB
David Nierengarten
Wedbush Securities
2 questions for NUVB
Kaveri Pohlman
BTIG, LLC
2 questions for NUVB
Silvan Türkcan
Citizens JMP
2 questions for NUVB
Soumit Roy
JonesTrading
2 questions for NUVB
Yaron Werber
TD Cowen
2 questions for NUVB
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
A large pharmaceutical company that has commercialized and/or is developing treatments for cancer, including therapies targeting hormone receptor pathways in cancer cells. These therapies are used for tumors such as ER+ mBC, prostate cancer, and ovarian cancer. | |
A large pharmaceutical company involved in the development of cancer therapies, including BET inhibitors for hematological malignancies and solid tumors. | |
A large pharmaceutical company developing cancer treatments, including therapies targeting hormone receptor pathways in cancer cells. | |
A large pharmaceutical company that has commercialized and/or is developing treatments for cancer. | |
A large pharmaceutical company involved in the development of cancer therapies, including hormone receptor-targeting treatments. | |
A large pharmaceutical company developing cancer treatments, including therapies targeting hormone receptor pathways in cancer cells. | |
A partnership involved in the development of cancer therapies. | |
Roche | A large pharmaceutical company developing cancer treatments, including therapies targeting hormone receptor pathways in cancer cells. |
Constellation Pharma/MorphoSys Company | A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. |
Opna Bio | A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. |
Plexxikon | A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. |
Zenith Epigenetics | A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. |
A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. | |
Boehringer Ingelheim | A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. |
A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. | |
Jacobio | A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. |
A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. | |
A large pharmaceutical company developing cancer treatments, including therapies targeting hormone receptor pathways in cancer cells and clinical-stage BET inhibitors. | |
Betta Pharmaceuticals | A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. |
Ranok Therapeutics | A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. |
Epigenetix | A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. |
Bayer | A large pharmaceutical company developing cancer treatments, including therapies targeting hormone receptor pathways in cancer cells. |
Clovis Oncology | A company developing cancer treatments, including therapies targeting hormone receptor pathways in cancer cells. |
Dendreon | A company developing cancer treatments, including therapies targeting hormone receptor pathways in cancer cells. |
Janssen Pharmaceutical Companies | A company developing cancer treatments, including therapies targeting hormone receptor pathways in cancer cells. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
AnHeart Therapeutics, Ltd. | 2025 | No specific deal value or structure details were provided; the integration into Nuvation Bio Inc. was completed via a merger which led to the departure of CEO Dr. Jerry Wang and was aimed at achieving regulatory approvals for taletrectinib. |
Recent press releases and 8-K filings for NUVB.
- Nuvation Bio reported $13.12 million in revenue for Q3 2025, primarily driven by the successful launch of its lead oncology product, IBTROZI, which targets ROS1-positive non-small cell lung cancer.
- Despite this revenue growth, the company posted a net loss of $55.8 million and a GAAP EPS of -$0.16, reflecting increased research and development and administrative expenses.
- The firm maintains a robust cash position of approximately $549 million, with cash and cash equivalents rising significantly from $35.723 million to $98.897 million during the quarter.
- Wall Street analysts maintain a unanimous 'buy' or 'strong buy' rating, with a median 12-month price target 48% above the recent close, indicating strong investor confidence in Nuvation Bio's growth potential.
- Nuvation Bio reported its first full quarter as a commercial-stage company in Q3 2025, achieving $13.1 million in total revenue, with $7.7 million from net product revenue of atrozine.
- Atrozine demonstrated strong market adoption with 204 new patients starting therapy in Q3 2025, averaging over 15 new patient starts per week.
- The median Duration of Response (DOR) for TKI-naive patients treated with atrozine increased to 50 months, and a supplemental New Drug Application (SNDA) to update the label is anticipated to be submitted by the end of the week.
- Regulatory approval for atrozine was received in Japan, with a $25 million milestone payment expected from Nippon Kayaku in Q4 2025 upon reimbursement approval.
- Nuvation Bio is advancing saflosotinib, an IDH1 inhibitor, into a pivotal Phase III study for high-grade IDH1-mutant glioma, citing promising clinical data and a significant market opportunity.
- Nuvation Bio reported a net loss of $55.8 million, or $(0.16) per share, for the third quarter ended September 30, 2025. This included $7.7 million in net product revenue from U.S. sales of IBTROZI and $5.4 million from collaboration and license agreements revenue.
- The company maintained a strong balance sheet with $549.0 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
- During the third quarter of 2025, 204 new patients started treatment with IBTROZI, and updated data as of August 2025 showed IBTROZI's median Duration of Response (DOR) increased to 50 months.
- Nuvation Bio enrolled the first patient in the TRUST-IV phase 3 study of IBTROZI and the G203 study for safusidenib, and anticipates a $25 million milestone payment by year-end 2025 following IBTROZI's approval in Japan.
- Nuvation Bio Inc. reported cash, cash equivalents, and marketable securities of $549.0 million as of September 30, 2025.
- For the three months ended September 30, 2025, the company generated net product revenue of approximately $7.7 million from U.S. sales of IBTROZI and reported a net loss of $55.8 million, or $(0.16) per share.
- In the third quarter of 2025, 204 new patients started treatment with IBTROZI (taletrectinib), and its median Duration of Response (DOR) increased to 50 months as of an August 2025 data cut-off.
- Nippon Kayaku received approval for IBTROZI from Japan's Ministry of Health, Labour and Welfare in September 2025, with Nuvation Bio expecting a $25 million milestone payment upon the first establishment of the reimbursement price by year-end.
- The company enrolled the first patient in the global, randomized G203 study of safusidenib for maintenance treatment of high-grade IDH1-mutant glioma in October 2025.
- Nuvation Bio's IBTROZI (taletrectinib), a next-generation ROS1 inhibitor, has received regulatory approvals for advanced ROS1+ NSCLC in the U.S. (June 11, 2025), Japan (September 2025), and China (January 2025).
- As of July 31, 2025, the U.S. launch of IBTROZI saw 70 patients start treatment within the first seven weeks.
- The company reported a strong cash position of $608 million as of June 30, 2025, which includes $200 million in non-dilutive capital from Sagard Healthcare Partners, providing a path to profitability without needing additional funding.
- Nuvation Bio estimates a theoretical maximum U.S. ROS1+ NSCLC market opportunity for IBTROZI of approximately $3.8 billion.